<DOC>
	<DOCNO>NCT00301769</DOCNO>
	<brief_summary>This phase I trial study side effect best dose SJG-136 treating patient relapse refractory acute leukemia , myelodysplastic syndrome , blastic phase chronic myelogenous leukemia , chronic lymphocytic leukemia . Drugs use chemotherapy , SJG-136 , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>SJG-136 Treating Patients With Relapsed Refractory Acute Leukemia , Myelodysplastic Syndromes , Blastic Phase Chronic Myelogenous Leukemia , Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Establish maximum tolerate dose SJG-136 patient relapse refractory acute myeloid leukemia ( AML ) , acute lymphoblastic leukemia ( ALL ) myelodysplastic syndrome ( MDS ) , chronic myelogenous leukemia blastic phase ( CML-BP ) , chronic lymphocytic leukemia ( CLL ) . II . Determine dose-limiting toxicity pharmacokinetics drug patient . OUTLINE : This dose-escalation study . Patients receive SJG-136 IV 15 minute day 1-5 . Courses repeat every 21 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos SJG-136 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A total 10 patient treated MTD .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<criteria>Diagnosis 1 follow hematologic malignancy : Acute myeloid leukemia Acute lymphoblastic leukemia Myelodysplastic syndromes Chronic myelogenous leukemia blastic phase Chronic lymphocytic leukemia Relapsed refractory disease No immediately available , potentially curable option ( e.g. , stem cell transplantation ) available Bilirubin normal ( unless elevate due Gilbert 's syndrome ) HIV positivity allow provide CD4 count normal AIDSdefining disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit study compliance Recovered prior therapy ECOG performance status = &lt; 2 SGOT SGPT = &lt; 2.5 time upper limit normal ( ULN ) Creatinine normal OR creatinine clearance &gt; = 60 mL/min Primary resistance ( i.e. , fail achieve complete remission [ CR ] standard induction regimen ) relapse achievement CR . Must document failure last cytotoxic regimen prior study entry . Ability understand willingness sign write informed consent document . No known CNS disease No history allergic reaction attribute compound similar chemical biologic composition SJG136 More 7 day since radiotherapy No concurrent combination antiretroviral therapy HIVpositive patient No antileukemia agent except hydroxyurea = &lt; 5 grams/day = &lt; 14 day prior first course treatment control blood count</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>